241
0 Kommentare
Beyond Air Schedules Fiscal Year End 2024 Financial Results Conference Call and Webcast
Conference call scheduled for Monday, June 24th at 4:30 pm ET
GARDEN CITY, N.Y., May 23, 2024 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on
harnessing the power of endogenous and exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders and solid tumors (through its
affiliate Beyond Cancer, Ltd. (“Beyond Cancer”)), today announced that it will report financial results for its fiscal fourth quarter and full year ended March 31, 2024 on Monday, June 24, 2024.
The Company’s management team is scheduled to host a conference call and webcast at 4:30 pm Eastern Time the same day.
Conference Call & Webcast | ||
Monday, June 24th @ 4:30 PM ET | ||
Domestic: |
1-877-407-0784 | |
International: | 1-201-689-8560 | |
Conference ID: | 13746892 | |
Webcast: | A webcast of the live conference call can be accessed by visiting the Events section of the Company’s website (click here) or directly (click here). An online replay will be available on the Company’s website or via the direct link an hour after the call. | |
Lesen Sie auch
About Beyond Air, Inc.
Beyond Air is a commercial stage medical device and biopharmaceutical company dedicated to harnessing the power of endogenous and
exogenous nitric oxide (NO) to improve the lives of patients suffering from respiratory illnesses, neurological disorders, and solid tumors. The Company has received FDA approval for its first
system, LungFit PH, for the treatment of term and near-term neonates with hypoxic respiratory failure. Beyond Air is currently advancing its other revolutionary LungFit systems in clinical trials
for the treatment of severe lung infections such as viral community-acquired pneumonia (including COVID-19), and nontuberculous mycobacteria (NTM) among others. Also, the Company has also partnered
with The Hebrew University of Jerusalem to advance a pre-clinical program dedicated to the treatment of autism spectrum disorder (ASD) and other neurological disorders. Additionally, Beyond Cancer,
Ltd., an affiliate of Beyond Air, is investigating ultra-high concentrations of NO with a proprietary delivery system to target certain solid tumors in the pre-clinical setting. For more
information, visit www.beyondair.net.